Published in Hepatitis Weekly, December 15th, 1997
Bristol-Myers Squibb receives exclusive development and marketing rights to any HCV protease inhibitors produced in the collaboration. In return, Bristol-Myers Squibb provides research funding as well as up-front, milestone, and royalty payments to Arris.
According to the terms of the agreement, Arris applies its proprietary Delta Technology to design potent and selective inhibitors of the protease...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly